EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties

Ladislav Prener iD, Ondřej Baszczyňski, Martin M Kaiser, Martin Dračínský, George Stepan, Yu-Jen Lee, Boris Brumshtein, Helen Yu, Petr Jansa, Eric B Lansdon iD, Zlatko Janeba iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.2c01574 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Ladislav Prener und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, Prague 6 160 00, Czech Republic. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV-1, HIV Infections. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute of Organic Chemistry and Biochemistry, Chinese Academy of Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) represent cornerstones of current regimens for treatment of human immunodeficiency virus type 1 (HIV-1) infections. However, NNRTIs usually suffer from low aqueous solubility and the emergence of resistant viral strains. In the present work, novel bicyclic NNRTIs derived from etravirine (ETV) and rilpivirine (RPV), bearing modified purine, tetrahydropteridine, and pyrimidodiazepine cores, were designed and prepared. Compounds 2, 4, and 6 carrying the acrylonitrile moiety displayed single-digit nanomolar activities against the wild-type (WT) virus (EC50 = 2.5, 2.7, and 3.0 nM, respectively), where the low nanomolar activity was retained against HXB2 (EC50 = 2.2-2.8 nM) and the K103N and Y181C mutated strains (fold change, 1.2-6.7×). Most importantly, compound 2 exhibited significantly improved phosphate-buffered saline solubility (10.4 μM) compared to ETV and RPV (≪1 μM). Additionally, the binding modes of compounds 2, 4, and 6 to the reverse transcriptase were studied by X-ray crystallography.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV-1HIV InfectionsHumansReverse Transcriptase InhibitorsHIV Reverse TranscriptaseRilpivirineDrug DesignNitrilesPyrimidines

Substanzen

Anti-HIV AgentsReverse Transcriptase InhibitorsHIV Reverse TranscriptaseRilpivirineetravirineNitrilesPyrimidines

Autor:innen und Institutionen

  • Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, Prague 6 160 00, Czech Republic.
  • Department of Organic Chemistry, Faculty of Science, Charles University, Hlavova 8, Prague 2 128 43, Czech Republic.
  • Gilead Sciences Inc., 333 Lakeside Drive, Foster City, California 94404, United States.

ORCID-Profile: Ladislav Prener, Eric B Lansdon, Zlatko Janeba

Förderung

  • Institute of Organic Chemistry and Biochemistry, Chinese Academy of Sciences

Zitieren

APA

Prener, L., Baszczyňski, O., Kaiser, M. M., Dračínský, M., Stepan, G., Lee, Y. J., Brumshtein, B., Yu, H., Jansa, P., Lansdon, E. B., & Janeba, Z. (2023). Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01574

Vancouver

Prener L, Baszczyňski O, Kaiser MM, Dračínský M, Stepan G, Lee YJ, et al. Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01574

BibTeX
@article{Prener2023,
  author = {Prener, Ladislav and Baszczyňski, Ondřej and Kaiser, Martin M and Dračínský, Martin and Stepan, George and Lee, Yu-Jen and Brumshtein, Boris and Yu, Helen and Jansa, Petr and Lansdon, Eric B and Janeba, Zlatko},
  title = {Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.2c01574}
}
Kostenlos starten →